ReviewAdvances in pediatrics2022
Clinical Indications for Growth Hormone Therapy.
Review in Advances in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis.BMC pediatrics · 2025Pooled it
- Safety and effectiveness of a biosimilar somatropin (Cinnatropin®) in children and adolescents receiving growth hormone therapy over 1 year: a registry-based phase IV study.European journal of pediatrics · 2025Trial
- Dose-response relationship between growth hormone treatment and the development of scoliosis in children with short stature.Annals of medicine · 2026Article
- High-yield soluble expression and affinity-tag-free purification of growth hormone receptor antagonist B2036 in Escherichia coli.Bioprocess and biosystems engineering · 2026Article
- Healthy short stature.Archives of endocrinology and metabolism · 2026Review
- Design, Synthesis, and Proof-of-Concept Bioassay of an Encapsulated mRNA for Human Growth Hormone.Current issues in molecular biology · 2026Article
- Clinical and genetic spectrum of SHOX deficiency: phenotypic heterogeneity and the "Jumping SHOX" phenomenon.European journal of pediatrics · 2026Article
- Atypical "opened-bottle" proximal tibial fractures in young male patients with growth hormone and aromatase inhibitor treatment: case series.Skeletal radiology · 2026Article
- Changes in Bioelectrical Impedance Analysis and Lipid Profile in Children Diagnosed with Short Stature Who Undergo Growth Hormone Therapy: One Single-Center Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Long-Term experience with growth hormone therapy in pediatric growth disorders: an analysis of the LG growth study data.Endocrine · 2026Observational
- Treatment with long-acting growth hormone: effectiveness and safety.Frontiers in endocrinology · 2026Review
- A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design.Therapeutic advances in endocrinology and metabolism · 2026Article
- Identification of a novel and a recurrentFrontiers in genetics · 2026Article
- Case Report: Exceptional longevity in turner syndrome.Frontiers in aging · 2026Article
- A retrospective analysis of real-world height outcomes of growth hormone treatment in Syrian children.BMC endocrine disorders · 2025Article
- Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy.Neurology. Genetics · 2025Article
- Diagnostic Challenges of Short Stature and Growth Hormone Insufficiency Across Different Genetic Etiologies.Biomedicines · 2025Review
- Review
- Concurrent mutations in RNU4ATAC, PLEC, and CD96 in a child with severe short stature and skeletal dysplasia: a case report.Italian journal of pediatrics · 2025Article
- 24-Week jumping exercise influence on growth speed and GH-IGF-1-IGFBP-3 axis among short-stature children.BMC pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Growth hormone (GH) is an injectable medication originally used to replace the deficiency of the hormone, but has expanded to treating conditions that may reduce growth and adult height even when the body maintains endogenous GH production. In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Willi Syndrome, small for gestational age (SGA) without catch-up growth, idiopathic short stature, Turner syndrome, SHOX gene haploinsufficiency, Noonan Syndrome, and chronic renal insufficiency. We characterize the growth patterns and effects of GH treatment in each of these indications. We also review patterns of growth that warrant referral to a pediatric endocrinologist, as well as safety updates. This review is intended to guide practitioners on the initial evaluation and management of patients with short stature, and the indications for GH therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.